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ABSTRACT 
Objective: To report the haematological parameters and coagulation times for cats with a congenital 
portosystemic shunt (CPSS) and the influence of surgical shunt attenuation on these parameters. To 
identify any association between prolongation in coagulation profiles and incidence of peri-operative 
haemorrhage. 
  
Methods: Retrospective clinical study using client owned cats with a CPSS. Signalment, shunt type 
(extrahepatic or intrahepatic), degree of shunt attenuation (complete or partial), haematological 
parameters, PT and aPTT test results and occurrence of any peri-operative clinical bleeding 
complications were recorded for cats undergoing surgical treatment of a CPSS at the Royal 
Veterinary College between 1994 and 2011. 
  
Results: Fourty-two cats were included. Thirty-six cats (87.5%) had an extrahepatic CPSS and six 
(14.3%) had an intrahepatic CPSS. Pre-operatively, mean cell volume (MCV) and mean cell 
haemoglobin (MCH) were below the reference interval in 32 (76.2%) and 31 (73.8%) cats 
respectively. Red blood cell count (RBC) and mean cell haemoglobin concentration (MCHC) were 
above the reference interval in 10 (23.8%) and eight (19.1%) cats respectively. Postoperatively, there 
were significant increases in HCT (P = 0.044), MCV (P = 0.008) and MCH (P = 0.002). Despite the 
significant increase in MCV post-operatively, the median MCV post-operatively was below the 
reference interval indicating persistence of microcytosis. Preoperatively, PT was above the upper 
reference interval in 14 cats (87.5%), and aPTT was above the upper reference interval in 11 cats 
(68.7%). No cat demonstrated a peri-operative clinical bleeding complication.  
  
Conclusions: Cats with a CPSS are likely to present with a microcytosis, but rarely present with 
anaemia, leukocytosis or thrombocytopenia. Surgical attenuation of the CPSS results in a significant 
increase in the HCT and MCV. Coagulation profiles in cats with a CPSS are likely to be prolonged, 
irrespective of shunt type, but do not appear to be associated with an increased risk of clinical 
bleeding.  
 
MANUSCRIPT 
Introduction 
A congenital portosystemic shunt (CPSS) is an aberrant connection between the portal and systemic 
circulations, where venous blood from the gastrointestinal tract, pancreas and spleen does not filter 
through the hepatic parenchyma and sinusoids. This results in an underdeveloped and poorly 
functioning liver. As the liver has an important role in the production of the majority of the 
coagulation factors, animals with impaired liver function are thought to be at increased risk of 
developing a coagulopathy. Most studies assessing coagulation in dogs with a CPSS or other hepatic 
disease have investigated for the presence of hypocoagulability,1-4 and one study has identified 
hypercoagulability in some dogs with a CPSS.5  
Previous studies of dogs with CPSS have shown that 35-84% had microcytosis and 16-70% were 
anaemic, whilst 7-53% had a prolonged prothrombin time, and 5-64% had a prolonged activated 
partial thromboplastin time (aPTT).1, 3-10 A leukocytosis is variably present with documented 
prevalence of between 15.4-40%.1, 8, 9, 11 A prospective study of dogs with CPSS showed that pre-
operatively, when compared with healthy dogs, they had lower platelet counts, prolonged aPTT and 
lower activity of some coagulation factors. Immediately post-operatively, the platelet counts 
decreased, the PT was prolonged and activity of coagulation factors previously reduced were 
increased. Six weeks post-operatively, dogs with no further shunting had improved coagulation 
times and further increased activity of coagulation factors.3  
In a number of studies of dogs with a CPSS, aPTT and PT are variably prolonged, however, this rarely 
results in clinical bleeding, and these changes have not been shown to be predictive of the ability to 
attenuate the shunt.1, 3, 4, 9, 12, 13 Incidences of haemorrhage, as a result of coagulopathy, in dogs 
undergoing surgery for CPSS attenuation have been documented but are rare in the literature.13-15  
The red blood cell parameters for cats with CPSS are reported in four studies including 130 cats in 
total with 25-54% having a microcytosis, and 0-15% being anaemic,16-19 In one study, 33% of cats had 
microcytosis without a concurrent anaemia.19  There is less information regarding coagulation 
parameters in cats with a CPSS with, to the authors’ knowledge, only one study reporting the 
haematology and coagulation parameters of a series of six cats with portal vein thrombosis, three of 
which were ultimately diagnosed with CPSS.20 Results were not reported for individual cats making 
interpretation of these results with relation to the CPSS difficult.  
Dogs with a CPSS variably have a leukocytosis, which is postulated to be multifactorial. Factors 
theorised to be involved include chronic stress, and inflammation as a result of hepatic 
encephalopathy, and inadequate hepatic clearance of bacteria and endotoxin.11, 21 A recent study 
has shown that surgical attenuation of a CPSS in dogs reduces the inflammation associated with 
hepatic encephalopathy, reflected as a significant reduction in the neutrophil and monocyte counts 
postoperatively.11 Information regarding leukocyte parameters in cats with a CPSS is lacking in the 
literature.  
The objectives of this study were to report the haematological (red and white blood cell) 
parameters, PT and aPTT of cats with a CPSS and evaluate the influence of surgical correction of the 
shunt on these parameters. We also examined the data for any association between prolongations 
in coagulation times or abnormalities in platelet count, and risk of peri-operative clinical 
haemorrhage. Our study hypotheses were that cats with a CPSS would have prolongations in PT and 
aPTT, microcytic anaemia and leukocytosis with similar prevalence to that reported for dogs and that 
these abnormalities would improve following attenuation of the CPSS. In addition, we hypothesised 
that these parameters would be similar between cats with extrahepatic and intrahepatic CPSS and 
not be predictive for the ability to completely attenuate the shunt. We further hypothesised that any 
abnormalities in coagulation parameters would correlate with the incidence of peri-operative 
bleeding complications.   
 
Materials and Methods 
The medical records of cats referred to the Queen Mother Hospital for Animals (QMHA) for surgical 
attenuation of a CPSS between November 1994 and June 2011 were retrospectively reviewed. Cats 
were treated with either partial or complete suture ligation of their CPSS depending on objective 
and subjective assessment of portal hypertension. A mesenteric vessel was catheterised and 
connected to a water manometer, allowing direct portal pressure measurement. The authors limited 
the increase in portal pressure to less than 10cmH2O/8mmHg, or less than double the base pressure 
prior to occlusion.22 Additionally, the central venous pressure and systemic arterial pressure were 
monitored during ligation, as well as changes in the colour of splanchnic viscera, as further indicators 
of changes in portal pressure. Only cats with haematology profiles submitted to the diagnostic 
laboratory at the authors’ institution were included in this study. Some cats also had coagulation 
profiles assessed, but this was at the attending clinician’s discretion. Clinical data collected included 
sex, age at time of surgery, breed, CPSS type (extrahepatic or intrahepatic), degree of CPSS 
attenuation at surgery (complete or partial) and details of any peri-operative clinical bleeding 
complications.  
Pre-operative and, where available, follow up post-operative haematological and coagulation 
parameters were recorded. This included complete blood count (CBC) data, red blood cell count 
(RBC), haemoglobin (Hb), haematocrit (HCT), mean cell volume (MCV), mean cell haemoglobin 
(MCH), mean cell haemoglobin concentration (MCHC), red blood cell distribution width (RBCDW), 
platelet count (PLT), white blood cell count (WBC), neutrophils, lymphocytes, monocytes, 
eosinophils, basophils, PT and aPTT. For haematology blood was taken and placed in an EDTA tube 
and analysed the same day. Haematology was performed using an Abbott Cell-Dyn 3500 (Abbott 
Diagnostics Limited, Berkshire, UK) as previously described.23 At least a 100-white blood cell manual 
differential count was undertaken to establish the concentrations of neutrophils, monocytes, 
lymphocytes, eosinophils and basophils. Blood smears were evaluated according to the diagnostic 
laboratory protocol, with review by a Board-certified veterinary clinical pathologist where further 
assessment was necessary. For coagulation tests, blood was placed in a sodium citrate tube and 
immediately transferred to the laboratory for evaluation without delay. Coagulation tests were 
performed between 1994 and 1998 using an Amelung Coagulometer (Burkard Scientific Ltd, 
Middlesex, UK) and between 1998 and 2011 using a STart 4 Hemostasis Analyzer (Diagnostica Stago 
UK Ltd, Theale, UK).  
Statistical Evaluation 
Analysis was performed using IBM SPSS Statistics 20.0.0 software package (Education SPSS (UK) 
Limited IBM). Continuous data were assessed for normality visually and with the Kolmogorov-
Smirnov test.  Mean and standard deviation were reported for parametric data, which were 
compared with a Paired Sample T test. The median and range were reported for skewed data, which 
were compared with a Wilcoxon Signed Rank test. Percentages were reported for categorical data, 
which were compared with a Fisher’s Exact test. For all tests significance was set at the 5% level (P ≤ 
0.05).  
 
Results 
Study Population 
Forty-two cats were included in the study. Twenty-eight cats (66.7%) were male, and 14 were 
neutered (33.3%). Fourteen cats (33.3%) were female, with eight (19%) being spayed.  Twenty-one 
cats (50.0%) were pedigree breeds including British short hair (5), Ragdoll (4), Persian (4), Siamese 
(2), Tonkinese (2), and one each of American Short Hair, Birman, Burmilla and Maine Coon. There 
were 18 domestic shorthair and three domestic longhair cats. The median age at time of surgery was 
9 months (range 3-115 months). 
Thirty-six cats (85.7%) had an extrahepatic CPSS and six (14.3%) had an intrahepatic CPSS. Twenty-
seven cats (64.3%) had partial CPSS attenuation and 15 cats (35.7%) had complete CPSS attenuation. 
There was no significant difference in the degree of attenuation based on the type of shunt with 2/6 
cats (33.3%) with an intrahepatic CPSS and 13/36 cats (36.1%) with extrahepatic CPSS tolerating 
complete attenuation (P = 1.00). There were no incidences of peri-operative haemorrhage in any cat.  
 
Complete Blood Counts (CBC) 
CBCs were available for all cats pre-operatively (table 1). The mean values of the study population 
for red blood cell parameters were below the reference interval for MCV and MCH. MCV and MCH 
were below the reference interval in 32 (76.2%) and 31 (73.8%) cats respectively. Both were below 
the reference interval in 28 cats (66.7%). There was no difference in the proportion of cats with 
microcytosis based on the type of CPSS or the degree of attenuation at surgery. All cats had normal 
platelet counts confirmed on a fresh blood smear. Only one cat had a HCT below the reference 
interval.  The mean or median values for all white blood cell parameters were within the reference 
intervals. Only one cat had an increased total white blood cell count (2.4%). Lymphocytes were 
below the reference interval in eight (19.1%) cats.  
 
Twenty-one cats (50.0%) had follow-up blood samples for CBC taken a median of four months after 
surgery (range 1-72 months). Nineteen cats (90.5%) had an extrahepatic CPSS and two (9.5%) had an 
intrahepatic CPSS. Nineteen cats (90.5%) had been treated with a partial attenuation and two (9.5%) 
had been treated with a complete attenuation. Paired pre and postoperative CBC are summarised in 
table 2. There were significant increases in mean or median study population values for haematocrit 
(HCT) (P = 0.044), mean cell volume (MCV) (P = 0.008) and mean cell haemoglobin (MCH) (P = 0.002).  
 
Coagulation profiles (table 3) 
Sixteen cats (38.1%) had pre-operative assessment of PT and aPTT at the discretion of the surgeon, 
independent of their clinical presentation. Thirteen cats (81.2%) had an extrahepatic CPSS and three 
(18.8%) had an intrahepatic CPSS. Eleven cats (68.7%) had partial shunt attenuation, whilst five cats 
(31.3%) had complete shunt attenuation. The PT was normal in two cats (12.5%) and prolonged in 
fourteen cats (87.5%). The aPTT was normal in three cats (18.7%), shortened in 2 cats (12.5%) and 
prolonged in eleven cats (68.8%). The PT was not greater than 1.5 times the maximal reference limit 
in any cat. The aPTT was greater than 1.5 times the maximal reference limit in five cats (31.3%).  
 
Six cats had follow-up assessment of coagulation profiles a median of 5.5 months (range 2-69 
months) after surgery.  Five cats (83.3%) had an extrahepatic CPSS, that were treated by partial 
shunt attenuation. One cat (16.7%) had an intrahepatic CPSS that was treated by complete shunt 
attenuation. Five of six cats (83.3%) had prolonged PT and aPTT. Only two of these cats had paired 
pre and postoperative samples. In these two cats both PT and aPTT were increased before and after 
surgery. 
 
Discussion 
This is a novel study reporting haematological and coagulation profiles in a series of cats undergoing 
surgical attenuation of a CPSS.  
 
Non-regenerative anaemia is a common finding in dogs with CPSS, with the literature documenting a 
prevalence of between 16%-46.2%.1, 6, 8-10 In contrast only one cat (2.4%) with a CPSS had a 
haematocrit below the reference interval in this study, which is a similar reported prevalence as that 
found in previous studies on cats with CPSS.16, 18, 19 The reason for this difference in presentation is 
unknown, but a significant increase in haematocrit (within the normal interval) was documented 
within 4 weeks of surgical attenuation of the CPSS in this population of cats, even though the 
majority had only been treated with partial attenuation. Follow up coagulation profiles were not 
performed for abnormal pre-operative results in this population.   The exact pathophysiology of 
anaemia in dogs with CPSS has not been ascertained.24 However, it is typically microcytic and 
hypochromic, and low serum iron concentrations have been identified in several dogs with CPSS, all 
of which suggests iron metabolism may be involved in the aetiology.6, 7, 25  Similarly, the exact reason 
why microcytosis develops in animals with CPSS is unknown, but in dogs it is postulated to be a 
result of impaired iron transport due to the inability of the liver to produce enough transferrin, 
resulting in increased iron sequestration in Kupffer cells and decreased serum iron levels.21, 25 
Additionally, animals with CPSS have abnormal lipid metabolism, which can result in alterations in 
erythrocyte membrane triglycerides and cholesterol content, causing the erythrocyte to become 
smaller.6  Further studies have failed to clearly identify an anaemia of inflammatory or chronic 
disease.6, 26 The exact mechanism of anaemia in dogs with CPSS is probably multifactorial and 
requires further investigation. No feline specific literature exists. 
Microcytosis, with or without anaemia, is a common finding (33%-84.6%) in dogs with a CPSS,1, 6, 8, 27 
and was seen in 76.2% of the cats in this study. This is a greater prevalence than 27-54% previously 
reported for cats with CPSS, and the reasons for this are unclear, although it is obvious from the 
wide ranges reported in the previous dog and cat studies that much variation is possible and the 
higher rate reported in this study is within the range reported for dogs.21, 28 As has been reported for 
dogs with a CPSS, the MCV significantly increased  after surgical attenuation.21, 27, 29 Pre-operatively, 
32 cats (76.2%) had an MCV below the reference interval, compared to 12 of 21 cats (57.1%) post-
operatively, with nine of 21 cats (42.9%) having an MCV within the reference interval. However, the 
median of our study population remained below the reference interval despite the increase in 
erythrocyte size.  This improvement was associated with similar improvements in HCT suggesting 
that this abnormality is reversible with improvements in portal blood flow. The presence of 
microcytosis was not associated with shunt type or predictive of the ability to completely attenuate 
the shunt, in this study, although the number of cats was relatively small. 
A decrease in MCH was seen in this population of cats prior to surgery which is likely related to the 
low MCV, rather than a reflection of decreased haemoglobin concentrations in these cells as the 
MCHC was within normal limits. The increase in MCHC seen in this study is artefactual, and is 
typically associated with haemolysis within the sample.  No gross haemolysis was seen in any of the 
cats. An increase in the RBC count was documented in 23.8% of our cats, however the significance of 
this in the face of a normal HCT is unknown. Further studies on the haematology of cats with CPSS is 
required to investigate these findings.  
The majority of cats with a CPSS that were tested (n= 16) had prolonged PT (87.5%) and aPTT 
(68.8%) prior to surgery. In comparison, some reports in dogs with a CPSS show PT and / or aPTT 
tests were significantly increased compared with a control population.1, 3, 5 Conversely, two studies in 
dogs with CPSS document both PT and aPTT within reference intervals.4, 8 These contradictory results 
highlight both the importance of approaching each animal with a CPSS individually, and the necessity 
to further research more reliable methods of assessing coagulation status in both dogs and cats with 
CPSS. Numbers were not considered adequate to allow statistical comparison of coagulation times 
based on the type of CPSS and the degree of attenuation.  
None of the cats with CPSS in this study showed clinical signs of coagulopathy or developed a 
complication relating to haemorrhage through the period of hospitalisation for surgical attenuation 
of their shunt. Whilst the sample size in this study is small, it does suggest that the cats with 
prolonged PT and aPTT tests prior to surgery are not at increased risk of developing a clinical peri-
operative bleeding complication. There are reports of dogs with CPSS suffering serious or fatal 
postoperative haemorrhage,13-15, 30 but overt bleeding is overall an uncommon complication in 
animals with a CPSS, severe liver disease or failure.1, 3, 5, 8, 31 One possible theory for why many of 
these animals do not become hypocoagulable is that the pro-coagulant system is not affected in 
isolation.20, 32, 33 The liver’s role in the coagulation system is complex, with significant roles in both 
the pro- and anti-coagulant systems. The liver also produces inhibitors of coagulation and 
fibrinolysis, as well as fibrinolytic proteins, and is responsible for clearing proteins of both systems 
from the circulation to prevent them from having a prolonged effect.2, 32, 34 aPTT and PT assays only 
evaluate secondary haemostasis in-vitro, and provide no information on primary haemostasis or the 
anti-coagulant system, giving the clinician minimal information on haemostasis as a whole. In 
addition, whilst they can identify clinically significant hypocoagulable states they are not able to 
identify hypercoagulable states, nor are they predictive of procedural bleeding.2, 27, 33, 35,36  More 
thorough evaluation of coagulation can be made through the use of viscoelastic testing, e.g. 
thromboelastography (TEG). Viscoelastic testing allows measurement of all stages of coagulation in-
vitro, including the anti-coagulant and fibrinolytic systems, giving a more complete view of 
coagulation status.34, 36 In addition it allows determination of hyper-coagulability.36 A study 
investigating the use of TEG in dogs with CPSS revealed that whilst 52% of dogs had a prolonged PT 
and none had a prolonged aPTT compared with a control population, the TEG results showed a 
significantly shorter K value in all 21 dogs with a CPSS, although only 2 dogs were below the 
reference interval.5 Additionally there was an increased angle, MA and G value in 2/21, 6/21 and 
9/21 dogs respectively, all of which are consistent with a hypercoagulable state.5 This suggests that 
some dogs with a CPSS may be hypercoagulable and highlights the importance of assessing the 
entire coagulation system, both pro and anticoagulation pathways. Studies on the use of TEG  in 
healthy cats have demonstrated variable results, with some producing reliable, reproducible results, 
indicating that this may be a useful technique for the assessment of the coagulation cascade in 
cats.37, 38 Another study has shown less reliability with the method, after excluding 15 of 40 samples 
from the final analysis due to > 20% variability for ≥ 2 variables.39 There are no reports yet of the use 
of TEG in cats with CPSS and this will be important to include in future studies.  
 
In the current study the median values of all white blood cell parameters were within the reference 
interval. A lymphocytosis was present in one cat (2.4%) and eight cats (19.1%) had a lymphopenia. 
There is limited information on white blood cell parameters in cats with CPSS. Previous studies have 
identified a lymphocytosis in 8.3-25% of cats and a lymphopenia in 12.8-25% of cats, which is similar 
to our findings.16, 19 These findings in cats are different to dogs with CPSS, where a leukocytosis, as a 
result of neutrophilia and/or a lymphocytosis, is a more common finding, being present in 15.4-40% 
of dogs.1, 8, 9, 11 This leukocytosis in dogs is thought to be related to inflammation due to inadequate 
hepatic clearance of lipopolysaccharide (LPS) and chronic stress.11, 40 A recent study showed 
evidence of reduced inflammation following CPSS attenuation in dogs in the form of reduction in 
neutrophil concentration, monocyte concentration and C-reactive protein.11 It is unclear why cats 
with CPSS do not demonstrate increased white blood cell counts similar to dogs. It is also interesting 
that a greater proportion of cats show a lymphopenia. This may be related to species differences in 
the response to stress.  
 
The retrospective nature of the project carries inherent issues with small study size and data 
collection. There were only two paired samples for pre and postoperative coagulation profiles, 
preventing assessment of improvement in coagulation times, and inability to draw conclusions 
regarding whether the shunt is able to be attenuated or not. Similarly, the time period between 
surgery and collection of the post-operative blood sample was inconsistent across the study 
population. This makes it difficult to conclude how quickly haematological and coagulation 
abnormalities normalise after surgical attenuation. The lack of a control group (not possible in this 
clinical setting with client owned cats) means we do not have a population of healthy cats 
undergoing surgery but unaffected by a CPSS to compare our results to, which makes it difficult to 
accurately conclude that the changes seen were due to CPSS attenuation itself. The coagulation 
system was assessed in cats using PT and aPTT as this was the routine method employed during the 
study period.  These have been shown to have poor correlation with clinical bleeding, in certain 
circumstances. As such, further investigation in to newer techniques, such as TEG, in cats with CPSS 
would be beneficial. Despite the limitations of the retrospective nature of this study, the data for 
feline CPSS is novel, and interesting differences and similarities are noted for haematological 
parameters and coagulation profiles compared with those reported in dogs with a CPSS.  
 
Conclusions 
Unlike dogs, cats with a CPSS are unlikely to be anaemic even though the majority will have 
microcytosis. Despite this, the HCT of cats with a CPSS significantly increased following surgical 
attenuation, as did the microcytosis, demonstrating that these changes are potentially reversible 
when hepatic portal flow is improved. Microcytosis was not associated with CPSS type or ability to 
completely attenuate the CPSS in this population of cats. Based on the current study, coagulation (PT 
and aPTT) profiles in cats with a CPSS are likely to be mildly prolonged. PT and aPTT tests in cats with 
a CPSS appear to give limited information with regards to the risk of a clinical bleeding complication 
during surgery.   
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Variable Number 
of cats 
Reference 
Interval 
Mean Standard 
deviation 
Median Range Number lower 
than reference 
interval (%) 
Number higher 
than reference 
interval (%) 
Red blood cells – RBC (x1012/L) 42 5.0-10.0 8.9 1.7   1 (2.4) 10 (23.8) 
Haemoglobin  - Hb (g/dL) 42 8.0-15.0 10.9 2.1   1 (2.4) 0 (0.0) 
Haematocrit  - HCT (%) 42 24.0-45.0 32.2 6.1   1 (2.4) 0 (0.0) 
Mean cell volume – MCV  (fL) 42 39.0-55.0 36.5 3.0   32 (76.2) 0 (0.0) 
Mean cell haemoglobin – MCH  42 13.0-17.5 12.3 1.0   31 (73.8) 0 (0.0) 
Mean cell haemoglobin concentration – MCHC 
(g/dL) 
42 30.0-36.0 33.9 1.9   2 (4.8) 8 (19.1) 
Red blood cell distribution width – RBCDW (%) 41  21.3 2.6     
Platelets (x109/dL) 42 200.0-800.0   208.5 32.9-1082.0 21 (50.0) 2 (4.8) 
         
White blood cells – WBC (x109/dL) 42 5.5-19.5 11.4 3.6   0 (0.0) 1 (2.4) 
Neutrophils (x109/dL) 42 2.5-12.5 7.1 2.4   0 (0.0) 1 (2.4) 
Lymphocytes (x109/dL) 42 1.5-7.0 3.5 2.3   8 (19.1) 1 (2.4) 
Monocytes (x109/dL) 42 0.0-1.5 0.4 0.3   0 (0.0) 0 (0.0) 
Eosinophils (x109/dL) 42 0.0-1.5   0.3 0.0-1.6 0 (0.0) 1 (2.4) 
Basophils (x109/dL) 42 0.0-0.4   0.0 0.0-0.3 0 (0.0) 0 (0.0) 
Table 1. Pre-operative haematological values for CPSS cats 
 
Variable Number 
of cats 
Reference 
interval 
Preoperative assessment Postoperative assessment P 
valu
e 
Mean Standard 
deviation  
Median Range Mean Standard 
deviation  
Median Range 
Red blood cells – RBC (x1012/L) 21 5.0-10.0 8.9 1.0   9.1 1.5   0.53
3 
Haemoglobin  - Hb (g/dL) 21 8.0-15.0   10.2 8.5-13.0   11.7 7.9-14.3 0.05
8 
Haematocrit  - HCT (%) 21 24.0-45.0 32.1 4.3   34.6 5.5   0.04
4 
Mean cell volume – MCV  (fL) 21 39.0-55.0   35.3 31.6-44.0   37.5 33.6-46.6 0.00
8 
Mean cell haemoglobin – MCH  21 13.0-17.5   12.2 10.2-14.3   13.1 10.8-37.3 0.00
2 
Mean cell haemoglobin 
concentration – MCHC (g/dL) 
21 30.0-36.0   33.7 29.1-37.9   32.7 25.4-37.0 0.43
4 
Red blood cell distribution 
width – RBCDW (%) 
20    21.1 17.8-29.7   21.0 16.0-23.9 0.32
2 
Platelets (x109/dL) 20 200.0-
800.0 
  234.0 32.9-747.0   178.5 33.1-684.0 0.88
1 
            
White blood cells – WBC 
(x109/dL) 
21 5.5-19.5   10.7 6.3-18.7   9.3 4.8-42.0 0.49
8 
Neutrophils (x109/dL) 21 2.5-12.5   7.0 3.3-11.6   4.7 1.8-16.8 0.14
0 
Lymphocytes (x109/dL) 21 1.5-7.0   3.0 0.6-6.3   3.34 1.3-30.2 0.93
1 
Monocytes (x109/dL) 21 0.0-1.5   0.4 0.0-0.7   0.2 0.0-39.0 0.84
8 
Eosinophils (x109/dL) 21 0.0-1.5   0.3 0.0-1.6   0.5 0.0-1.8 0.06
3 
Basophils (x109/dL) 21 0.0-0.4   0.0 0.0-0.2   0.0 0.0-8.91 0.32
6 
 
Table 2. Paired pre and postoperative haematological data for cats that underwent surgical attenuation of a CPSS 
 
 
 
 
Variable Number 
of cats 
Reference 
interval 
Mean Standard 
deviation 
Number lower 
than reference 
interval (%) 
Number higher 
than reference 
interval (%) 
Complete 
attenuation (%) 
Partial 
attenuation (%) 
Preoperative         
Prothrombin time – PT (seconds) 16 7.0-11.0 12.3 1.7 0 (0) 14 (87.5) 6 (42.9) 8 (57.1) 
Activated partial thromoboplastin time – 
APTT (seconds) 
16 13.0-20.0 24.7 9.6 2 (12.5) 11 (68.8) 4 (36.4) 7 (63.6) 
         
Postoperative         
Prothrombin time – PT (seconds) 6 7.0-11.0 12.0 0.7 0 (0) 5 (83.3) 1 (20) 4 (80) 
Activated partial thromoboplastin time – 
APTT (seconds) 
6 13.0-20.0 29.3 10.5 0 (0) 5 (83.3) 1 (20) 4 (80) 
 
Table 3. Pre and postoperative PT and aPTT results for cats that underwent surgical attenuation of a CPSS 
Complete attenuation: number of cats with prolonged PT or APTT that underwent complete attenuation 
Partial attenuation: number of cats with prolonged PT or APTT that underwent partial attenuation 
 
